2020
Absolute Lymphocyte Counts Are Not a Biomarker of Clinical Response in Patients Treated With Delayed-Release Dimethyl Fumarate (830)
Longbrake E, Mao-Draayer Y, Matthews P, Foley J, Zieliński T, Chen C, Mokliatchouk O, Parks B, Sharma A, Xing D, Kapadia S, Bame E. Absolute Lymphocyte Counts Are Not a Biomarker of Clinical Response in Patients Treated With Delayed-Release Dimethyl Fumarate (830). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.830.Peer-Reviewed Original Research
2015
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal - Experimental Translational And Clinical 2015, 1: 2055217315596994. PMID: 26550483, PMCID: PMC4636217, DOI: 10.1177/2055217315596994.Peer-Reviewed Original ResearchDimethyl fumarateMultiple sclerosisRisk factorsClinical significanceGrade 2Lower baseline absolute lymphocyte countBaseline absolute lymphocyte countSingle academic medical centerDMF-induced lymphopeniaDMF-treated patientsRetrospective cohort studyAbsolute lymphocyte countGood clinical responseProgressive multifocal leukoencephalopathyDisease-modifying therapiesFraction of patientsReal-world populationAcademic medical centerLymphocyte monitoringNatalizumab exposureMultifocal leukoencephalopathyClinical responseCohort studyLymphocyte countOlder patients